PharmStar Pharmaceuticals, Inc. Names Dr. Antonio Hernandez to Medical Advisory Board

WILSON, NC--(Marketwire - August 10, 2011) -

PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the “Company”) announced today that Dr. Antonio Hernandez has accepted an invitation to join the Company’s Medical Advisory Board (MAB).

The Medical Advisory Board will be instrumental in overseeing the protocols established for the Company’s 3rd party claims testing, and develop testing protocols for future product offerings by the Company. While Aquaprin needs no further development and testing as an OTC product, the Board will establish protocols for developing a prescription strength version of the Company’s future product line. Additionally, the Board will assist in guiding products to the medical community to help ensure doctors’ endorsement of the Aquaprin product line. This will aid in the commercial success of the Aquaprin technology.

Dr. Hernandez has served as a hematopathologist in Orlando, Florida since 2009. Before moving to Florida, he served in the same capacity for Kaiser Permanente in Los Angeles, beginning in 1994. He received his M.D. from the University of Miami School of Medicine in 1987. Dr. Hernandez is certified by the American Board of Pathology, and is a member of the American Society of Hematology (ASH) and the Florida Society of Pathologists.

“I am pleased to join the Medical Advisory Board for PharmStar,” stated Dr. Hernandez. “Providing new products for medical treatment is important because it introduces new options for therapy and for modifying disease course, and Aquaprin is no different. I have been involved with PharmStar for a few years, and am honored to take a critical role in bringing this to market. I hope that our work on the Advisory Board will provide beneficial information about Aquaprin’s safety, advantage and utility, and at the same time meet the needs of the Board of Directors.”

Dr. Hernandez continued, “I applaud Mr. Phykitt for developing this Advisory Board. It shows concern and respect for the retail public in general and the medical profession in particular.”

CEO Howard Phykitt stated, “I am happy that Dr. Hernandez has decided to accept our invitation, and become a member of this important Board. He is a caring and passionate physician, and will be a positive influence on the path we create to bring Aquaprin to market.”

About PharmStar Pharmaceuticals, Inc.
PharmStar Pharmaceuticals, Inc. (“PharmStar”) is a U.S.-based drug development, manufacturing and marketing company and the innovator of the FDA-approved liquid pain reliever, Aquaprin™. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin, and is now ready for commercialization. Aquaprin™'s unique, multiple patent-pending formulas are designed to dissolve nearly instantly in just 1.5 ounces or more of water. This enables the product to be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset.

PharmStar initially plans to sell Aquaprin™ directly to nursing homes, outpatient and health care clinics, emergency units of hospitals nationwide, as well as retail distribution in selected local markets and third-party websites to be announced. All package engineering, product stability, shelf life testing and quality control research has been completed. PharmStar’s headquarters are located in Wilson, NC. www.pharmstarinc.com

Forward-Looking Statements Disclosure

This press release includes “forward-looking statements” within the meaning of the federal securities laws, commonly identified by such terms as “believes,” “will,” “looking ahead,” “anticipates,” “estimates” and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company’s projections and expectations are disclosed in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.